Some Pharmacogical Adverse Effects of Moxifloxacin and Staphylococcal Aureus in Rats

A.A.Elkomy1, R.M.Elshafae2, M.H.Mohamed3, F.I.Elsayed4 and S.M.Elshafae5"


Moxifloxacin is a broad spectrum fluoroquinolone antibacterial agent. We examined the plasma biomarkers of hepatorenal adverse effects of moxifloxacin ,lipid profile and blood glucose in rat following administration of moxifloxacin (MXF). Thirty-six Wistar rats, 200–250 g, were randomized into four groups (I–IV). Animals in group I (control) received 3.3 mL of distilled water, while animals in groups II administrated with moxifloxacin received 3.3 mL each of MXF equivalent to 26.4 mg/kg b.wt respectively for five successive days, III while animals in this group experimentally infected with staphylococcal aureus, and IV while animals in this group first experimentally infected with staphylococcal infection then received 3.3 mL each of moxifloxacine equivalent to 26.4 mg/kg b.wt respectively for five successive days. After seven days, plasma urea, bilirubin, and creatinine were significantly elevated in the MXF-treated animals. Activities of alkaline phosphatase, aspartate aminotransferase, and alanine aminotransferase were significantly increased in the plasma of MXF-treated animals compared to control. Also plasma total cholesterol, HDL-cholesterol, LDL-cholesterol, and triglycerides increased significantly in the MXF-treated groups relative to control. Moreover, a significant increase in serum glucose concentration ,a significant decrease in blood Hb concentration and white blood cells)WBCs concentration (key words,MXF moxifloxacin ,HDL high density lipoprotein ,LDL low density lipoprotein .

Key words

MXF moxifloxacin , HDL high density lipoprotein, LDL low density lipoprotein.